Biogen (NASDAQ:BIIB) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Biogen (NASDAQ:BIIB) from a strong sell rating to a hold rating in a research note released on Tuesday morning,Zacks.com reports.

Several other analysts have also recently issued reports on the company. Bank of America reduced their price objective on Biogen from $217.00 to $215.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 21st. Jefferies Financial Group reissued a “buy” rating on shares of Biogen in a research note on Monday, July 13th. Wall Street Zen upgraded Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Barclays increased their price target on Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Wednesday. Finally, Canaccord Genuity Group lifted their price objective on Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a research note on Wednesday, April 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $221.11.

Biogen Trading Up 1.9%

Shares of BIIB stock opened at $209.43 on Tuesday. Biogen has a fifty-two week low of $124.56 and a fifty-two week high of $219.72. The company has a 50 day moving average price of $200.68 and a 200 day moving average price of $190.37. The stock has a market capitalization of $30.92 billion, a P/E ratio of 22.47 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same period in the prior year, the business earned $5.47 EPS. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts predict that Biogen will post 11.28 EPS for the current fiscal year.

Institutional Trading of Biogen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Biogen by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock worth $3,070,514,000 after acquiring an additional 157,857 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Biogen by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock worth $736,435,000 after acquiring an additional 130,618 shares in the last quarter. Norges Bank purchased a new stake in Biogen during the fourth quarter worth approximately $464,408,000. Invesco Ltd. lifted its stake in Biogen by 4.2% during the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after purchasing an additional 98,001 shares during the last quarter. Finally, Morgan Stanley boosted its holdings in Biogen by 3.3% in the fourth quarter. Morgan Stanley now owns 2,325,013 shares of the biotechnology company’s stock valued at $409,180,000 after purchasing an additional 73,478 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of approximately $2.74 billion, up 3.4% year over year and above the roughly $2.46 billion consensus estimate. Adjusted EPS of $3.60 also exceeded expectations, supporting the positive market reaction. Reuters article
• Positive Sentiment: The Growth Portfolio generated $1.06 billion in revenue, up 24% year over year and ahead of the legacy multiple sclerosis portfolio. SKYCLARYS, ZURZUVAE, and products acquired through the Apellis transaction—including SYFOVRE and EMPAVELI—provided important growth contributions. The Pharma Letter article
• Positive Sentiment: Biogen raised its full-year 2026 revenue outlook to mid-single-digit growth versus 2025, reflecting momentum in newer drugs and the Apellis acquisition. Analysts also highlighted pipeline progress, including encouraging early Alzheimer’s data for diranersen. Seeking Alpha article
• Neutral Sentiment: Leqembi sales continued to grow, reaching 29.3 billion yen globally in the quarter, but narrowly missed some expectations. The Alzheimer’s drug remains strategically important, although its near-term contribution is being weighed against commercialization costs and competition. Leqembi sales article
• Negative Sentiment: GAAP net income fell sharply to $97.5 million from $634.8 million a year earlier, while reported EPS declined to $0.66 from $5.47. Biogen’s updated 2026 non-GAAP EPS guidance of $12 to $13 is below the prior consensus estimate of $13.45, tempering the otherwise strong earnings reaction. The Wall Street Journal article
• Negative Sentiment: Legacy multiple sclerosis products remained under pressure, highlighting Biogen’s continuing dependence on successful execution of its newer rare-disease, Alzheimer’s, and acquired-product portfolio.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.